SCHEMBL12862811

SCHEMBL12862811

CC(C)C1CCc2nc3ccccc3c(=O)n21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.49
GAA P10253 1/20 0.49
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 3/20 0.47
BCHE P06276 2/20 0.47
ACHE P22303 2/20 0.47
USP2 O75604 1/20 0.47
CYP1A2 P05177 1/20 0.47
CFTR P13569 1/20 0.47
HKDC1 Q2TB90 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GOPC Q9HD26 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ATM Q13315 2/20 0.46
CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15160572 0.81 ALOX15 (0.52) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL12529604 0.79 CASP1 (0.55) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL12624640 0.77 CASP1 (0.58) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL14079628 0.76 CASP1 (0.60) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL926740 0.76 CASP1 (0.60) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL32681143 0.75 ALDH1A1 (0.47) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL12529625 0.75 CASP1 (0.48) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL12529991 0.72 CASP1 (0.51) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL927372 0.72 CASP1 (0.56) ALOX15GAAALDH1A1KDM4EBCHE
SCHEMBL28093327 0.69 GAA (0.59) ALOX15GAAALDH1A1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501786-B2 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US disclosed
EP-2274296-B1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2012-10-17 EP disclosed
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2011-02-03 US disclosed
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 ALOX15 2308/4885GAA 3210/4885ALDH1A1 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.